Karyopharm Therapeutics (KPTI) Net Income (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Net Income came in at $131.4 million in Q4 2025, up 187.72% YoY from $45.7 million in Q4 2024, and up 496.62% on a QoQ basis from -$33.1 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Net Income (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Net Income data on file, last reported at $131.4 million in Q4 2025.
- Quarterly Net Income rose 187.72% year-over-year to $131.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $37.5 million (up 163143.48% YoY) and the FY2025 annual result came in at $37.5 million, up 163143.48% from the prior year.
- Net Income climbed to $131.4 million in Q4 2025, from -$33.1 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $131.4 million in Q4 2025 to a low of -$57.4 million in Q1 2021.
- A 5-year average of -$12.6 million and a median of -$34.3 million in 2023 frame the typical range for Net Income.
- Annual changes were most pronounced in 2023 — Net Income jumped 356.63% — and 2025, when it slumped 256.57%.
- Tracing KPTI's Net Income over 5 years: stood at $38.7 million in 2021, then plunged by 201.83% to -$39.4 million in 2022, then jumped by 356.63% to $101.2 million in 2023, then sank by 54.87% to $45.7 million in 2024, then soared by 187.72% to $131.4 million in 2025.
- The last three Net Income figures came in at $131.4 million (Q4 2025), -$33.1 million (Q3 2025), and -$37.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | -67.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -67.02 Mn |
| Dec 31, 2025 | 131.39 Mn |
| Sep 30, 2025 | -33.13 Mn |
| Jun 30, 2025 | -37.25 Mn |
| Mar 31, 2025 | -23.46 Mn |
| Dec 31, 2024 | 45.67 Mn |
| Sep 30, 2024 | -32.07 Mn |
| Jun 30, 2024 | 23.79 Mn |
| Mar 31, 2024 | -37.36 Mn |
| Dec 31, 2023 | 101.19 Mn |
| Sep 30, 2023 | -34.51 Mn |
| Jun 30, 2023 | -32.63 Mn |
| Mar 31, 2023 | -34.13 Mn |
| Dec 31, 2022 | -39.43 Mn |
| Sep 30, 2022 | -36.32 Mn |
| Jun 30, 2022 | -49.06 Mn |
| Mar 31, 2022 | -41.40 Mn |
| Dec 31, 2021 | 38.72 Mn |
| Sep 30, 2021 | -51.81 Mn |
| Jun 30, 2021 | -53.58 Mn |